SCHEMBL19935405

SCHEMBL19935405

CC(C)(C)C(=O)OCOC(=O)c1cc(=O)c2c(OCC(F)COc3cccc4oc(C(=O)OCOC(=O)C(C)(C)C)cc(=O)c34)cccc2o1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GPR35 Q9HC97 2/20 0.52
▸ LMNA P02545 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ KMT2A Q03164 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ ABCG2 Q9UNQ0 9/20 0.40
▸ ABCB1 P08183 2/20 0.39
▸ MAOB P27338 1/20 0.39
▸ ADRB2 P07550 3/20 0.38
▸ NMT2 O60551 2/20 0.38
▸ ADRB1 P08588 2/20 0.38
▸ ADRB3 P13945 2/20 0.38
▸ NMT1 P30419 2/20 0.38
▸ BCHE P06276 1/20 0.36
▸ ACHE P22303 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19935582 0.91 GPR35 (0.64) GPR35LMNATDP1KMT2AMEN1
SCHEMBL144592 0.85 GPR35 (0.58) GPR35LMNATDP1KMT2AMEN1
SCHEMBL22102054 0.84 GPR35 (0.57) GPR35LMNATDP1KMT2AMEN1
SCHEMBL24600022 0.82 GPR35 (0.47) GPR35LMNATDP1KMT2AMEN1
SCHEMBL27108983 0.82 GPR35 (0.47) GPR35LMNATDP1KMT2AMEN1
SCHEMBL25669938 0.82 GPR35 (0.54) GPR35LMNATDP1KMT2AMEN1
SCHEMBL25472684 0.81 GPR35 (0.62) GPR35LMNATDP1KMT2AMEN1
SCHEMBL115418 0.80 GPR35 (0.52) GPR35LMNATDP1KMT2AMEN1
SCHEMBL115378 0.80 GPR35 (0.52) GPR35LMNATDP1KMT2AMEN1
SCHEMBL26848988 0.80 GPR35 (0.52) GPR35LMNATDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3506894-B1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES MASSACHUSETTS GEN HOSPITAL (US) 2023-08-23 — — EP disclosed
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases THE GENERAL HOSPITAL CORPORATION (US) 2023-06-20 — — US disclosed
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases THE GENERAL HOSPITAL CORPORATION (US) 2023-06-20 — — US disclosed
US-20190240194-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES THE GENERAL HOSPITAL CORPORATION 2019-08-08 — — US disclosed
WO-2018045217-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES THE GENERAL HOSPITAL CORPORATION (US) 2018-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190240194-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES CD68, PRNP, HTT GPR35 1528/4885LMNA 755/4885TDP1 3376/4885
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases CD68, PRNP, HTT GPR35 1528/4885LMNA 755/4885TDP1 3376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback